ABDIBIO
PRODUCTION CENTER

A strong testament to Abdi İbrahim’s endeavor to open a world-class biopharmaceutical production facility, AbdiBio commenced its operations in May 2018 in its Esenyurt Production Complex. Equipped with advanced technology, the purpose of this facility is to create a strong and wide-ranging biotech product portfolio and to heal more lives with these drugs.

In our facility built on a total indoor area of 13,500 m2, in which is performed all production processes starting from the cell bank to the final product, and manufacture products for the treatment of cancer, diabetes, rheumatism, central nervous system, eye and blood diseases. The facility boasts an annual output capacity of 11 million vials, 11 million syringes, 11 million lyophilised vials and 16 million cartridges.

AbdiBio Biopharmaceutical Production Facility delivers long-term value with its innovative products, as well as collating global know-how to be combined with local knowledge. While contributing more to the pharmaceutical industry with many innovative additions to our portfolio in the upcoming period, we also prioritize contributing to the reduction of the current account deficit with our exports.

• 

  We plan to export the products produced in AbdiBio to North Africa, CIS countries and Balkan countries in the next 2-3 years.

• 

  Empowering us to set ambitious goals for employment, AbdiBio will enable us to reverse human capital flight as we bring foreign experts specializing in this field that lacks qualified talent and make immense contributions to our industry and country by training Türkiye-based future experts.

• 

  In addition to our production operations at AbdiBio, in 2018 we launched the first biosimilar in the Turkish market upon obtaining a license for “CANHERA”, a therapeutic product that contains the active substance Trastuzumab and that is used in the treatment of metastatic breast cancer.

• 

  At Abdi İbrahim, we strive to deliver high-value-added projects through our R&D activities, which underpin our activities in the field of biotechnology. Our goal is to take part in all development stages, from cell to final product, and create a sustainable system, to produce the first domestic and national monoclonal antibody biosimilar, and to be the first Turkish pharmaceutical company to develop, produce and globally launch its own biotech product.

• 

  Representing Abdi İbrahim's vision regarding biotechnological transformation in the pharmaceutical industry, AbdiBio is an investment that bolsters the competitive edge of not only our company but also the Turkish pharmaceutical industry and adds value to the entire industry. Dedicated solely to the production of biotechnological products, AbdiBio will play a crucial role in reducing import dependency and boosting exports, thus remedying the current account deficit, which is the most important considerations for Türkiye’s economy.